Related references
Note: Only part of the references are listed.Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Ina Scholz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
Guo Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Johanna Weiss et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China
Lingling Chen et al.
PHARMACOGENOMICS (2008)
A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole
Shaoji Cheng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Steve Trifilio et al.
CANCER (2007)
Voriconazole therapeutic drug monitoring
J Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Pharmacokinetic/pharmacodynamic profile of voriconazole
Ursula Theuretzbacher et al.
CLINICAL PHARMACOKINETICS (2006)
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
BJ Kullberg et al.
LANCET (2005)
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
S Trifilio et al.
BONE MARROW TRANSPLANTATION (2005)
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status
Y Ikeda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
PM frequencies of major CYPs in Asians and Caucasians
T Mizutani
DRUG METABOLISM REVIEWS (2003)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
L Purkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
DW Denning et al.
CLINICAL INFECTIOUS DISEASES (2002)
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
JA Goldstein
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Share Paper
